Related Experiment Video
Updated: Nov 17, 2025
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
Published on: January 19, 2024
Application of micronised acellular dermal matrix for primary premature ejaculation: A preliminary study
Zhen Ma1,2, Ming Li1,2, Xue-Sheng Wang3
1Department of Urology, Shandong Provincial Hospital, Shandong, China.
Abstract:
This study aimed to explore the efficacy of injection of micronised acellular dermal matrix (MADM) particles for treating primary premature ejaculation. This study was a prospective single-arm clinical trial. Thirty patients who met the surgical indications were enrolled. MADM particles, mixed in platelet-rich plasma, were injected into Buck's fascia to spread over the dorsal penile nerve, suppress the influx of nerve impulses and, thus, reduce penis sensitivity. We evaluated the changes according to intravaginal ejaculation latency time using a stopwatch and a premature ejaculation diagnostic tool. Meanwhile, we also recorded sexual partner satisfaction and adverse events. All patients recovered well after surgery with no complications such as infections or allergies. The mean intravaginal ejaculation latency time before surgery was 0.72 ± 0.28 min, compared with 2.41 ± 0.54 min, 2.64 ± 0.41 min, 2.79 ± 0.25 min and 2.89 ± 0.35 min at, respectively, 4, 8, 16 and 20 weeks after surgery. The premature ejaculation diagnostic values and sexual partner satisfaction had significantly improved after treatment. Injection of MADM particles is an effective, safe and simple method for treating premature ejaculation.
Insights
Micronised acellular dermal matrix (MADM) particle injections effectively treat premature ejaculation by reducing penile sensitivity. This safe and simple procedure significantly improves intravaginal ejaculation latency time and sexual partner satisfaction.
Area of Science:
- Urology
- Regenerative Medicine
- Sexual Health
Background:
- Premature ejaculation (PE) is a common sexual dysfunction affecting many men.
- Current treatments for PE have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of injecting micronised acellular dermal matrix (MADM) particles for primary premature ejaculation.
- To assess the impact of MADM particle injections on intravaginal ejaculation latency time (IELT) and patient-reported outcomes.
Main Methods:
- A prospective single-arm clinical trial involving 30 patients with primary PE.
- MADM particles mixed with platelet-rich plasma were injected into Buck's fascia over the dorsal penile nerve.
- IELT, premature ejaculation diagnostic tool (PEDT) scores, and sexual partner satisfaction were assessed pre- and post-treatment.
Main Results:
- Mean IELT significantly increased from 0.72 min pre-surgery to 2.89 min at 20 weeks post-surgery.
- Significant improvements were observed in PEDT values and sexual partner satisfaction.
- No complications such as infections or allergies were reported, indicating a favorable safety profile.
Conclusions:
- Injection of MADM particles is a safe, effective, and simple treatment option for primary premature ejaculation.
- The procedure offers a promising therapeutic strategy for improving sexual function and quality of life in patients with PE.
